Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.61 |
| ▸ | JAK1 | P23458 | 12/20 | 0.61 |
| ▸ | TYK2 | P29597 | 10/20 | 0.61 |
| ▸ | JAK2 | O60674 | 8/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23878782 | 1.00 | JAK3 (0.61) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL22055383 | 0.97 | JAK2 (0.57) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL23879060 | 0.97 | JAK2 (0.57) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL22054218 | 0.90 | TYK2 (0.49) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL23878952 | 0.90 | TYK2 (0.49) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL30146792 | 0.90 | TYK2 (0.49) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL22054222 | 0.90 | JAK3 (0.50) | JAK3JAK1TYK2JAK2 | |
| SCHEMBL23879004 | 0.89 | TYK2 (0.47) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL30147242 | 0.89 | TYK2 (0.48) | JAK3JAK1TYK2JAK2PLK4 | |
| SCHEMBL23889625 | 0.89 | JAK2 (0.47) | JAK3JAK1TYK2JAK2PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| WO-2021238908-A1 | SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR | 上海翰森生物医药科技有限公司 | 2021-12-02 | — | — | WO | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | JAK3 88/4885JAK1 12/4885TYK2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.